scispace - formally typeset
Search or ask a question

Showing papers by "Jana Markova published in 2013"

Journal Article•DOI•
An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma

[...]

Annette E. Hay1, Beate Klimm, Bingshu E. Chen1, Helen Goergen, Lois E. Shepherd1, Michael Fuchs, Mary Gospodarowicz2, Peter Borchmann, Jean M. Connors3, Jana Markova4, Michael Crump2, Andreas Lohri, Jane N. Winter5, Bernd Dörken6, Robert Pearcey7, Volker Diehl, Sandra J. Horning8, Hans-Theodor Eich, Andreas Engert, Ralph M. Meyer1, Ralph M. Meyer9 •
Queen's University1, University of Toronto2, BC Cancer Agency3, Charles University in Prague4, Northwestern University5, Charité6, University of Alberta7, Stanford University8, Juravinski Hospital9
01 Dec 2013-Annals of Oncology
TL;DR: In patients with nonbulky stage IA-IIA Hodgkin lymphoma, CMT provides better disease control than ABVD alone, especially among those not achieving complete response after two cycles of ABVD.

41 citations

Journal Article•DOI•
DNMT3A mutations in AML: a new prognostic factor?

[...]

Jiří Schwarz, Jana Markova
01 Nov 2013-Leukemia Research
TL;DR: The aim of the metaanalysis was to increase robustness of the prognostic ata on DNMT3A mutations in AML so as to be able to advoate their testing at diagnosis of AML, and it seems that Shivarov et al. fulfilled the aim by demonstrating the utations’ influence even on OS.

2 citations

first-line chemotherapy in advanced-stage Hodgkin lymphoma progression or early relapse for patients with residual disease after Positron emission tomography has a high negative predictive value for

[...]

Peter Borchmann, Harald Schicha, Volker Diehl, Andreas Engert, Reinhard Lorenz, Mathias Schreckenberger, Roland Bares, Hans Theodor Eich, Rolf-Peter Mueller, Wolfram H. Knapp, Josee M. Zijlstra, Andreas Bockisch, Matthias Weckesser, Carsten Kobe, Markus Dietlein, Jeremy Franklin, Jana Markova, Andreas Lohri, Holger Amthauer 
01 Jan 2013
TL;DR: The results show clear trends in progeria-related morbidity and mortality in men and women aged 50 and over over a period of at least 20 years, and these trends are likely to continue for some time to come.
Abstract: doi:10.1182/blood-2008-06-155820Prepublished online August 29, 2008;2008 112: 3989-3994€€€€Fuchs, Peter Borchmann, Harald Schicha, Volker Diehl and Andreas EngertReinhard Lorenz, Mathias Schreckenberger, Roland Bares, Hans T. Eich, Rolf-Peter Mueller, MichaelSusanne Klutmann, Wolfram H. Knapp, Josee M. Zijlstra, Andreas Bockisch, Matthias Weckesser, Carsten Kobe, Markus Dietlein, Jeremy Franklin, Jana Markova, Andreas Lohri, Holger Amthauer,€

1 citations